阿托伐他汀对冠心病患者血清IL-33、KLF2、LP-PLA2水平的影响

Effects of atorvastatin on levels of serum IL-33,KLF2 and LP-PLA2 in patients with coronary heart disease

目的:分析阿托伐他汀对冠心病患者血清白细胞介素-33(IL-33)、锌指Krüppel样转录因2(KLF2)、脂蛋白相关磷脂酶A2(LP-PLA2)水平的影响。方法:回顾性分析我院经常规治疗(对照组)及经阿托伐他汀+常规治疗(观察组)的冠心病患者各64例临床资料。比较两组治疗前及治疗3个月后脂代谢指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症反应指标[白介素-6(IL-6)、白细胞介素-33(IL-33)、脂蛋白相关磷脂酶A2(LP-PLA2)]、细胞因子[细胞凋亡抑制因子(sFas)、锌指Krüppel样转录因2(KLF2)]差异,并记录两组治疗期间不良反应发生情况差异。结果:治疗3个月后,两组部分脂代谢指标(TC、TG、LDL-C)、炎症反应指标(IL-6、IL-33、LP-PLA2)及sFas水平均较治疗前降低,HDL-C、KLF2水平则较治疗前升高,且观察组变化幅度大于对照组。两组治疗期间不良反应发生情况比较,差异无统计学意义。结论:阿托伐他汀可降低冠心病患者血清IL-33、LP-PLA2水平,并促进血清KLF2水平升高,也能同时改善患者炎症反应、细胞凋亡过程及血管内皮功能,达到显著疗效。

Objective To analyze the effects of atorvastatin on levels of serum interleukin-33(IL-33),zinc finger Krüppel-like transcriptional factor 2(KLF2)and lipoprotein-associated phospholipase A2(LP-PLA2)in patients with coronary heart disease.Methods The clinical data of each 64 patients with coronary heart disease who underwent routine treatment(control group)and atorvastatin+routine treatment(observation group)were retrospectively analyzed.The lipid metabolism indicators[total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],inflammatory response indicators[interleukin-6(IL-6),interleukin-33(IL-33),lipoprotein-associated phospholipase A2(LP-PLA2)]and cytokines[apoptosis inhibitor(sFas),zinc finger Krüppel-like transcriptional factor 2(KLF2)]were compared between the two groups before treatment and after 3 months of treatment.And the occurrence of adverse reactions during treatment was recorded in the two groups.Results After 3 months of treatment,the levels of partial lipid metabolism indexes(TC,TG,LDL-C),inflammatory response indicators(IL-6,IL-33,LP-PLA2)and sFas were lower than those before treatment while the levels of HDL-C and KLF2 were higher than those before treatment,and the changes in observation group were greater than those in control group.There was no significant difference in the occurrence of adverse reactions during treatment between the two groups.Conclusions Atorvastatin can reduce the levels of serum IL-33 and LP-PLA2 in patients with coronary heart disease,and promote the increase of serum KLF2 level.And it can also improve the inflammatory response,apoptosis process and vascular endothelial function with significant efficacy.